Clinical outcomes of everolimus-eluting bioresorbable scaffolds or everolimus-eluting stents in patients with acute myocardial infarction: two-year results of the randomised ISAR-Absorb MI trial

Jens Wiebe; Robert A. Byrne; Fernando Alfonso; Michael Maeng; Christian Bradaric; Evgeny Kretov; Javier Cuesta; Constantin Kuna; Tareq Ibrahim; Fernando Rivero; Mira Heugl; Evald H. Christiansen; Michael Joner; Heribert Schunkert; Karl Ludwig Laugwitz; Adnan Kastrati; Salvatore Cassese

doi:10.4244/EIJ-D-21-00653

Clinical outcomes of everolimus-eluting bioresorbable scaffolds or everolimus-eluting stents in patients with acute myocardial infarction: two-year results of the randomised ISAR-Absorb MI trial

Jens Wiebe
, Robert A. Byrne
, Fernando Alfonso
, Michael Maeng
, Christian Bradaric
, Evgeny Kretov
, Javier Cuesta
, Constantin Kuna
, Tareq Ibrahim
, Fernando Rivero
, Mira Heugl
, Evald H. Christiansen
, Michael Joner
, Heribert Schunkert
, Karl Ludwig Laugwitz
, Adnan Kastrati
, Salvatore Cassese

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Original language	English
Pages (from-to)	1348-1351
Number of pages	4
Journal	EuroIntervention
Volume	17
Issue number	16
DOIs	https://doi.org/10.4244/EIJ-D-21-00653
State	Published - Mar 2022

Access to Document

10.4244/EIJ-D-21-00653

Cite this

Wiebe, J., Byrne, R. A., Alfonso, F., Maeng, M., Bradaric, C., Kretov, E., Cuesta, J., Kuna, C., Ibrahim, T., Rivero, F., Heugl, M., Christiansen, E. H., Joner, M., Schunkert, H., Laugwitz, K. L., Kastrati, A., & Cassese, S. (2022). Clinical outcomes of everolimus-eluting bioresorbable scaffolds or everolimus-eluting stents in patients with acute myocardial infarction: two-year results of the randomised ISAR-Absorb MI trial. EuroIntervention, 17(16), 1348-1351. https://doi.org/10.4244/EIJ-D-21-00653

@article{3384ac8fd8e742e2aa63e0cfcaa118a4,

title = "Clinical outcomes of everolimus-eluting bioresorbable scaffolds or everolimus-eluting stents in patients with acute myocardial infarction: two-year results of the randomised ISAR-Absorb MI trial",

author = "Jens Wiebe and Byrne, \{Robert A.\} and Fernando Alfonso and Michael Maeng and Christian Bradaric and Evgeny Kretov and Javier Cuesta and Constantin Kuna and Tareq Ibrahim and Fernando Rivero and Mira Heugl and Christiansen, \{Evald H.\} and Michael Joner and Heribert Schunkert and Laugwitz, \{Karl Ludwig\} and Adnan Kastrati and Salvatore Cassese",

note = "Funding Information: R.A. Byrne reports research funding to the institution of prior employment from CeloNova BioSciences, and research or educational funding to the institution of current employment from Abbott Vascular, Biosensors, Biotronik and Boston Scientific. M. Joner reports grants and personal fees from Edwards, personal fees from Recor, AstraZeneca, Amgen, Biotronik, Orbus Neich, Boston Scientific and Abbott, and grants from Boston Scientific. J. Wiebe reports other from AstraZeneca, outside the submitted work. H. Schunkert reports personal fees from Amgen, grants and personal fees from AstraZeneca, personal fees from Bayer Vital GmbH, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, MSD Sharp \& Dohme, Novartis, Sanofi-Aventis, Servier and SYNLAB. The other authors have no conflicts of interest to declare. Funding Information: The trial was sponsored by the Deutsches Herzzentrum M{\"u}nchen. The study was predominantly funded by the Deutsches Herzzentrum M{\"u}nchen and in part by a grant from Abbott Vascular.",

year = "2022",

month = mar,

doi = "10.4244/EIJ-D-21-00653",

language = "English",

volume = "17",

pages = "1348--1351",

journal = "EuroIntervention",

issn = "1774-024X",

publisher = "Europa Group",

number = "16",

}

Wiebe, J, Byrne, RA, Alfonso, F, Maeng, M, Bradaric, C, Kretov, E, Cuesta, J, Kuna, C, Ibrahim, T, Rivero, F, Heugl, M, Christiansen, EH, Joner, M , Schunkert, H , Laugwitz, KL , Kastrati, A & Cassese, S 2022, 'Clinical outcomes of everolimus-eluting bioresorbable scaffolds or everolimus-eluting stents in patients with acute myocardial infarction: two-year results of the randomised ISAR-Absorb MI trial', EuroIntervention, vol. 17, no. 16, pp. 1348-1351. https://doi.org/10.4244/EIJ-D-21-00653

Clinical outcomes of everolimus-eluting bioresorbable scaffolds or everolimus-eluting stents in patients with acute myocardial infarction: two-year results of the randomised ISAR-Absorb MI trial. / Wiebe, Jens; Byrne, Robert A.; Alfonso, Fernando et al.
In: EuroIntervention, Vol. 17, No. 16, 03.2022, p. 1348-1351.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Clinical outcomes of everolimus-eluting bioresorbable scaffolds or everolimus-eluting stents in patients with acute myocardial infarction

T2 - two-year results of the randomised ISAR-Absorb MI trial

AU - Wiebe, Jens

AU - Byrne, Robert A.

AU - Alfonso, Fernando

AU - Maeng, Michael

AU - Bradaric, Christian

AU - Kretov, Evgeny

AU - Cuesta, Javier

AU - Kuna, Constantin

AU - Ibrahim, Tareq

AU - Rivero, Fernando

AU - Heugl, Mira

AU - Christiansen, Evald H.

AU - Joner, Michael

AU - Schunkert, Heribert

AU - Laugwitz, Karl Ludwig

AU - Kastrati, Adnan

AU - Cassese, Salvatore

N1 - Funding Information: R.A. Byrne reports research funding to the institution of prior employment from CeloNova BioSciences, and research or educational funding to the institution of current employment from Abbott Vascular, Biosensors, Biotronik and Boston Scientific. M. Joner reports grants and personal fees from Edwards, personal fees from Recor, AstraZeneca, Amgen, Biotronik, Orbus Neich, Boston Scientific and Abbott, and grants from Boston Scientific. J. Wiebe reports other from AstraZeneca, outside the submitted work. H. Schunkert reports personal fees from Amgen, grants and personal fees from AstraZeneca, personal fees from Bayer Vital GmbH, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, MSD Sharp & Dohme, Novartis, Sanofi-Aventis, Servier and SYNLAB. The other authors have no conflicts of interest to declare. Funding Information: The trial was sponsored by the Deutsches Herzzentrum München. The study was predominantly funded by the Deutsches Herzzentrum München and in part by a grant from Abbott Vascular.

PY - 2022/3

Y1 - 2022/3

UR - https://www.scopus.com/pages/publications/85127729922

U2 - 10.4244/EIJ-D-21-00653

DO - 10.4244/EIJ-D-21-00653

M3 - Article

C2 - 34702694

AN - SCOPUS:85127729922

SN - 1774-024X

VL - 17

SP - 1348

EP - 1351

JO - EuroIntervention

JF - EuroIntervention

IS - 16

ER -

Clinical outcomes of everolimus-eluting bioresorbable scaffolds or everolimus-eluting stents in patients with acute myocardial infarction: two-year results of the randomised ISAR-Absorb MI trial

Access to Document

Other files and links

Cite this